Kornimate/medical-research-clean huggingface dataset:
investigation of relationship between contrast nephropathy and caval index measurement in patients with ileus in ed

Conditions: Ileus; Mechanical; Contrast-induced Nephropathy

Summary: in this study, the investigators aimed to evaluate the incidence of vena cava inferior diamater on ultrasound guidance of intravascular volume before diagnosis of contrast - enhanced ct for diagnostic purposes in ileus patients and to investigate the incidence and risk of developing contrast nephropathy due to contrast - enhanced ct.

our work will be carried out in kocaeli derince education and research hospital emergency service. patients who are scheduled to receive abdominal contrast computed tomography (ct) scans in the emergency room, who are over 18 years of age, who are referred to kocaeli derince education and research hospital emergency department for the study, will be calculated and recorded. the mehran risk scores will be calculated and recorded in our clinic. 3 ml / kg iv physiological saline (sf) is applied first and then 1 ml / kg / hr iv sf is applied for at least 6 hours after shots. in addition, patients with contrasted abdominal ct underwent emergency surveillance ultrasound imaging (including the measurement of the vena cava diameter for evaluation of the patient's volume status). patients who were admitted to our general surgery and not followed up for at least 48 hours, patients with contrast allergies, patients with renal replacement therapy, pregnancies, patients with contrast-enhanced ct scans within the last 10 days, and patients not informed will not be taken to the study. all emergency physicians will be informed about the study. less than 100 ml of hypoosmolar, non-ionic contrast material will be used for all ct shots. patients will be evaluated for the development of contrast nephropathy according to biochemical assays 48-72 hours after ct acquisition. physicians evaluating patients in the emergency and general surgery services will be required to record blood tests that they consider necessary for diagnostic and therapeutic purposes, and no extra blood will be collected for use in the study.

Eligibility criteria:
inclusion criteria: * patients who underwent contrast abdominal ct and were admitted to our general surgery department for at least 48 hours * written informed patients * patients older than 18 years exclusion criteria: * with contrast agent allergy * story of renal replacement therapy * contrast agent exposure within the last 10 days * pregnancy

Keywords: ileus contrast-induced nephropathy vena cava inferior
a phase 2 study of ts-172 in hyperphosphatemia patients on hemodialysis with phosphate binders

Conditions: Hyperphosphatemia Patients on Hemodialysis

Summary: a phase 2, randomized, placebo-controlled, double-blind, phosphate binder-combination study of ts-172 in hyperphosphatemia patients on hemodialysis


Eligibility criteria:
inclusion criteria: 1. hyperphosphatemia patients (outpatients) with chronic kidney disease receiving hemodialysis (hd or hdf) 3 times a week for at least 12 weeks prior to visit 1 (week -3) 2. patients aged \>= 18 years at the time of obtaining informed consent 3. patients with a serum phosphorus concentration of \>= 5.5 mg/dl and \< 10.0 mg/dl at visit 1 (week -3) 4. patients who have been prescribed at least one phosphate binder within the approved dosage, and the prescribed drug and dosage regimen should have been unchanged during the last 2 weeks prior to visit 1 (week -3) exclusion criteria: 1. patients with confirmed serum intact pth concentration \>500 pg/ml from visit 1 (week -3) to visit 4 (week 0) 2. patients who have undergone previous parathyroid intervention (ptx, peit, etc.)
an open-label pilot study of qualia senolytic supplementation for the attenuation of systemic inflammatory cytokines

Conditions: Inflammation

Summary: this open-label pilot study includes adults aged 45 to 79 residing in the united states. the study will last 7 days. participants will provide blood samples via an at-home finger-prick kit at baseline and day 7 and complete electronic surveys on health indicators at baseline, and days 3 and 7. all procedures are conducted remotely, with no in-person visits, to collect real-world evidence.

objectives within-group changes in outcomes will be compared from baseline to the end of the study period. primary outcome measures: biomarkers in blood, measured using the olink target 48 cytokine panel: tumor necrosis factor (tnf) interleukin-1 beta (il1b) interleukin-8 (cxcl8) vascular endothelial growth factor a (vegfa) secondary outcome measures: remaining biomarkers in the olink target 48 cytokine panel 36-item short form health survey (sf-36) frailty index for elders (fife) depression anxiety stress scale-21 (dass-21) side effect profile including: number, type, severity, causality, and outcome of adverse events or unanticipated problems symptoms of aging, assessed by: aging male symptom scale aging female symptom scale participant details: study duration per participant: 7 days total number of participants: 40

Eligibility criteria:
inclusion criteria: * provide voluntary, written, informed consent to participate in the study * agree to provide a valid cell phone number and are willing to receive communications through text. * healthy adults 45 - 79 years of age can read and write english * willing to not begin taking any new supplements during the study and continue taking any supplements they are currently using regularly. * willing to self-administer the fingerstick test kit at home for both a baseline and post-intervention blood sample, and to complete a release form that gives nhc access to the results of these tests. * willing to complete questionnaires, records, and diaries associated with the study. exclusion criteria: * women who are pregnant, breastfeeding, or planning to become pregnant during the trial * known food intolerances/allergy to any ingredients in the product * having any of the following conditions: psychiatric conditions, neurologic disorders, endocrine disorders, cancer * having had a significant cardiovascular event in the past 6 months * taking mao inhibitors, ssris, or any other psychiatric or neurological medicines * on immunosuppressive therapy * individuals who were deemed incompatible with the test protocol * adults lacking capacity to consent

Keywords: senolytic
evaluation of ev1000™/volumeview™ for cardiac output monitoring in liver transplantation

Conditions: Liver Disease

Summary: the investigators are trying to evaluate the agreement of cardiac output measurements taken using the specific thermistor-tipped arterial catheter ( the volumeview ™ catheter) and the ev1000 ™ monitoring platform ( edward lifesciences, irvine, ca, usa) with measurements taken using continuous pulmonary artery thermodilution cardiac output monitoring during orthotopic liver transplantation.

in cirrhotic patient undergoing liver transplantation, there are an altered patterm of circulation, which is characterized by increased cardiac output, decreased peripheral vascular resistance, and reduced ventricular response to physiological, pharmacological, and surgical stress. large blood loss and clamping/declamping of the inferior vena cava and portal vein during liver transplantation surgery can affect intravascular volume status, which in turn can lead to hemodynamic instability. therefore, reliable cardiac output monitoring is particularly useful in the cirrhotic patient undergoing liver transplant. pulmonary artery thermodilution has been used as a standard method for cardiac output assessment for many years. pulmonary artery catheter can cause rare but serious complications. and it has some limitations for continuously monitoring cardiac output during rapid hemodynamic changes. recently, several minimally invasive co monitors have been developed. the pulse contour technique continuously estimates co through mathematical analysis of the waveform of arterial pressure. however, previous studies evaluating the reliability of the pulse contour techniques indicated conflicting results in cirrhotic patients during liver transplantation. most of studies were performed by analyzing from radial artery pressure waveform. because of rapid changing of intravascular volume, using inotropics, the monitoring of femoral artery pressure has been recommended during liver transplantation. a new pulse wave analysis system has developed and introduced into clinical practice that consists of a specific thermistor -tipped femoral arterial catheter ( the volumeview™ catheter) and the ev1000™ monitoring platform ( edward lifesciences, irvine, ca, usa). to continuously assess co based on the femoral arterial pressure curve signal and it uses transpulmonary thermodilution for calibration. we are trying to evaluate the agreement of cardiac output measurements taken using ev1000™ / volumeview™ with measurements taken using continuous pulmonary artery thermodilution cardiac output monitoring during orthotopic liver transplantation.

Eligibility criteria:
inclusion criteria: subjects undergoing living donor liver transplantation during the study period subjects older than 20yrs who can give informed consent exclusion criteria: those who are confirmed moderate severe aortic regurgitation by echocardiography those with infection on cannulation site

Keywords: liver transplantation cardiac output
bladder cancer case control study of arsenic in water

Conditions: Bladder Cancer

Summary: this study is examining the relationship between ingested arsenic and bladder cancer in two areas of california where a large percentage of the population was exposed to drinking water containing arsenic at low to moderate levels.

water supplies in many parts of the world contain naturally occurring arsenic. previous studies have shown that arsenic at high doses can cause cancer of the bladder. the risk at lower doses is unknown. this study is examining the relationship between ingested arsenic and bladder cancer in central nevada and kings county, california, two areas where a large percentage of the population was exposed to drinking water containing arsenic at low to moderate levels. approximately 200 people with bladder cancer and 400 people without bladder cancer will be included. subjects are interviewed by telephone about past residences, occupations, diet, drinking water consumption, and other lifestyle factors. arsenic measurements in well water have been collected from the appropriate state agencies and are being matched with residences and drinking water consumption rates to estimate lifetime arsenic exposures for each subject. people with bladder cancer will then be compared to those without to see if people with cancer were more likely to have lived in areas with arsenic in their drinking water.

Eligibility criteria:
cases must meet the following criteria: * diagnosed with primary bladder cancer from january 1, 1997 until december 31, 2000. * live in the following counties at the time of diagnosis: churchill, lyon, mineral, storey, douglas, carson city, nevada, and kings county, california * ages 20-85 at the time of diagnosis. controls will be matched to cases based on gender and five year age groups.

Keywords: arsenic bladder cancer drinking water
overcoming resistance to egfr neutralization by combination of monoclonal antibodies and novel cancer drugs

Conditions: Non Small Cell Lung Cancer

Summary: the study is aimed at patients with advanced cancer and egfr mutation. some molecules recently discovered at the level of tumor tissue can influence the response to anti-egfr drugs. among these molecules is nrg1, which binds to the egfr receptor family. unravelling the mechanisms that give cancer cells resistance to such biologics could improve response to therapy and survival. and analyzing tumors during anti-egfr drug therapy used in clinical practice could allow us to perform analyses on nrg1 and hypothesize a possible strategy to increase survival

experimental, tissue study. patients with egfr receptor amplification/overexpression or activating mutations treated with anti-egfr cancer therapies will be involved in the study as required in normal clinical practice. clinical information of the patients, relevant to the conduct of the study, will be collected: age, sex, ethnicity, smoking habit, diagnosis, staging of the tumor, site of any metastases, possible presence of ascites and/or pleural effusion, type of oncological therapy administered, concomitant therapies, radiological re-evaluation of the tumor, response to treatment, survival. similarly, peripheral blood, tissue obtained from archival tumor biopsies, ascitic and/or pleural fluid samples (taken, if present, as per clinical practice) will be collected. primary cell cultures will be derived from tumor biopsies, ascites, and/or pleural effusion for in vitro studies the lymphocyte population will be isolated from the peripheral blood of patients

Eligibility criteria:
inclusion criteria: * patients aged ≥ 18 years * patients with advanced cancer characterized by amplification/overexpression or activating mutations of the egfr receptor. * patients who are candidates for treatment with tki and/or mabs both in the first and second line, according to clinical practice. * possibility of obtaining all information relating to the clinical history - obtaining written informed consent exclusion criteria: * patients who in the opinion of the investigator may not be compliant with the needs of the study * patients suffering from pathologies (e.g. psychiatric, neurological) that do not allow the obtaining of valid informed consent

Keywords: egfr mutation
digital life coaching for myeloma patients undergoing transplantation

Conditions: Multiple Myeloma

Summary: this is the first study of digital life coaching (dlc) to engage patients during the peri-hct period that is punctuated by intensive life changes. dlc may circumvent these limitations by combining the integrative cross-dimensional nature of life coaching with the advantages of mobile health technology. the purpose of this study is to evaluate whether ongoing participant engagement with a dlc platform is feasible for multiple myeloma (mm) patients actively undergoing hematopoietic stem cell transplantation (hct).

participants will receive unlimited access to pack health's dlc platform during a 16-week period encompassing pre-hct conditioning chemotherapy, post-hct recovery, and 100-day follow-up. participants will engage with pack health's dlc platform and complete quality of life assessments for 16 weeks beginning from enrollment. at the conclusion of the treatment period, participants will be asked to rate their satisfaction with the dlc platform primary objective: to evaluate the rate of ongoing participant engagement with a dlc platform during the study period secondary objectives: * to assess quality of life among participants during the study period * to assess psychosocial distress among participants during the study period * to assess sleep disturbances among participants during the study period * to assess participant satisfaction with the dlc platform at the end of the study period exploratory objectives: * to assess benzodiazepine and zolpidem-class drug usage for anxiety or insomnia among participants during the study period * to assess communications with treatment teams among participants during the study period * to assess 100-day clinical outcomes among participants at the end of the study period

Eligibility criteria:
inclusion criteria: * confirmed diagnosis of one of the following (all referred to as mm in this protocol): * multiple myeloma (icd-10 code: c90.0) * extramedullary plasmacytoma (icd-10 code: c90.2) * planned receipt of autologous hct at our institution * patients undergoing outpatient hct will be eligible * patients who received chemomobilization will be eligible * age ≥ 18, as life coaches employed by the dlc vendor are not currently trained to work with pediatric patients exclusion criteria: * prior autologous hct for any indication * physician-assessed lack of sufficient english proficiency * lack of ownership of a personal smartphone * any serious and/or unstable pre-existing medical, psychiatric, or other condition that could interfere with participant's safety, provision of informed consent, or compliance with study procedures

Keywords: multiple myeloma digital life coaching hematopoietic stem cell transplantation
bioxmark, rectal feasibility trial

Conditions: Rectal Cancer

Summary: to test the feasibility and accuracy of bioxmark fiducial markers for image guided radiotherapy (igrt) based rectal tumor boosting in 20 patients referred for long course chemo-radiotherapy of the locally advanced rectal cancer.

this study is a prospective non-randomized open label trial. a total of 20 patients who will undergo neo-adjuvant chemo-radiotherapy for rectal cancer will be included in this study upon informed consent. during an extra sigmoidoscopy after enema preparation, 4 liquid marker spots will be placed 1 cm from the tumor; two in the in the cranial and two in the caudal direction of the tumor (4 markers in total per patient). participants will undergo standard treatment for their rectal cancer. as part of standard patient set-up directly before each radiotherapy treatment, kilovoltage (kv) cone-beam computed tomography (cbct) will be acquired. treatment positioning will be based on the regular clinical decision protocols for treatment of rectal cancer and not on the markers. during treatment potential fiducial movement will be assessed using an externally positioned ultra-sound probe (this probe will be positioned against the abdominal or perineal skin of the patients depending on de position of the tumor/fiducials in the rectum). moreover, for patients in this study 2 orthogonal kv images will be made immediately after each radiation using the electronic portal imaging (epi) device. as part of standard clinical practice an magnetic resonance imaging (mri) of the rectum will be made for response evaluation 6-8 weeks after the end of neo-adjuvant chemo-radiotherapy. as part of standard clinical practice patients whose tumor has not responded completely will be operated on 8-12 weeks after the end of neoadjuvant chemo-radiotherapy. patients with a complete response will be follow-upped according to the "wait-and-see" protocol. cone-beam ct and mr images which are obtained as routine practice during treatment of the participants will be compared with images of 20 non-participating patients treated at our institute in the same period.

Eligibility criteria:
inclusion criteria: * patients with histological or cytological proven adenocarcinoma of the rectum, treated with long course external beam radiotherapy * age \> 18 years * have given written informed consent before patient registration exclusion criteria: * patients using anticoagulants: platelet aggregation inhibitors or coumarines * iodine allergy
establishing muscle impedance parameters with electrical impedance myography

Conditions: IBM; Inclusion Body Myositis

Summary: the primary aim of this study is to assess the changes in the impedance parameters of muscles in inclusion body myositis (ibm) through electrical impedance myography (eim), an emerging non-invasive electrodiagnostic technology. muscle impedance parameters can potentially serve as an objective biomarker reflecting disease progression and severity.

in this pilot study, the electrical impedance myography (eim) parameters of individuals with inclusion body myositis (ibm) will be compared with age and sex matched normal data. along with eim parameters, clinical outcome measures will be obtained to understand how eim data correlates with these parameters. a focused study to assess muscle health in ibm patients through eim is essential to gather further insight into the potential application of this technology as a disease biomarker. additionally, this investigation will provide critical data for the design of a subsequent biomarker validation study.

Eligibility criteria:
inclusion criteria: * clinico-pathologically defined ibm in the absence of any other significant neurological problem or cognitive dysfunction. * healthy controls will be age and gender-matched to the enrolled ibm patients. exclusion criteria for both ibm and control group: * patients with decompensated congestive heart failure * patients with chronic kidney disease on hemodialysis * patients with active cancer on chemotherapy or radiotherapy * patients with severe disease who are already wheel-chair bound

Keywords: electrical impedance myography eim
drug eluting balloon efficacy for small coronary vessel disease treatment

Conditions: Cardiovascular Diseases

Summary: this is a prospective, multicentre, randomized clinical study of consecutive patients with coronary artery disease in vessels with diameter ≤2.75 mm. patients will be randomized to drug-eluting balloon (deb) or standard therapy with second generation drug-eluting stent (des). study population will consist of 240 patients with stable or unstable angina


Eligibility criteria:
inclusion criteria 1. age \>18 years. 2. stable or unstable coronary artery disease. 3. native coronary artery lesion in vessel with diameter \<2.75 mm. 4. clinical indication to percutaneous coronary intervention (pci). exclusion criteria 1. enrolment in another study with any investigational drug or device. 2. acute or recent (≤48 hours) myocardial infarction. 3. creatinine clearance \<50 ml/min. 4. left ventricle ejection fraction \<30%. 5. any known allergy, hypersensitivity or intolerance to any drug used during or after the procedure. 6. heavily calcified and severely tortuous lesions.

Keywords: small vessels drug coated balloon
dry needling versus conventional physical therapy in patients with plantar fasciitis

Conditions: Plantar Fasciitis

Summary: the purpose of this research is to compare patient outcomes following treatment of plantar fasciitis with conventional physical therapy (stretching, strengthening, ultrasound, manual therapy, and cryotherapy) and conventional physical therapy plus dry needling. physical therapists commonly use conventional physical therapy techniques and dry needling to treat plantar fasciitis, and this study is attempting to find out if the addition of dry needling to conventional physical therapy is more effective than conventional physical therapy alone.

patients with plantar fasciitis will be randomly assigned to receive 1-2 treatments per week for 4 weeks of either: (1) dry needling and conventional physical therapy, or the (2) conventional physical therapy (stretching, strengthening, ultrasound, manual therapy, and cryotherapy)

Eligibility criteria:
inclusion criteria: 1. report of at least 3 months of heel pain 2. patient has not had physical therapy, massage therapy, chiropractic treatment, or injections for plantar heel pain in the least 4 weeks. 3. diagnosis of plantar heel pain with all of the following positive clinical signs: * "first---step" pain upon weight bearing in the morning or after sitting for a period of time * pain localized over the medial calcaneal tubercle * increased pain with extended walking or standing \>15 minutes 4. plantar heel pain greater than or equal to 2/10 (nprs 0-10 scale) exclusion criteria: 1. report of red flags to manual physical therapy to include: hypertension, infection, diabetes, peripheral neuropathy, heart disease, stroke, chronic ischemia, edema, severe varicosities, tumor, metabolic disease, prolonged steroid use, fracture, ra, osteoporosis, severe vascular disease, malignancy, etc. 2. history of previous surgery to the tibia, fibula, ankle joint, or foot. 3. history of arthrosis or arthritis of the ankle and/or foot. 4. history of significant ankle and/or foot instability. 5. two or more positive neurologic signs consistent with nerve root compression, including any two of the following: * muscle weakness involving a major lower extremity muscle group * diminished lower extremity patella or achilles tendon reflexes * diminished / absent sensation in any lower extremity dermatome 6. involvement in litigation or worker's compensation regarding their foot pain. 7. any condition that might contraindicate the use of electro---needling 8. the patient is pregnant